Idiopathic Pulmonary Fibrosis Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	339 Pages	Coherent Market Insights	May, 2023	CMI18001221

Best Price Guarantee
Price	from $4,500
Length	339 Pages
Publisher	Coherent Market Insights
Published Date	May, 2023
SKU	CMI18001221

Idiopathic Pulmonary Fibrosis Market, By Drug (Pirfenidone, Nintedanib, Others (Interferon gamma-1b and Others)), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Phamacies), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults, in the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). The diagnosis of IPF requires exclusion of other forms of interstitial pneumonia including other idiopathic interstitial pneumonias (IIP) and interstitial lung disease (ILD) associated with environmental exposure, medication, or connective tissue disease.

Market Dynamics

Increasing prevalence of Idiopathic pulmonary fibrosis is expected to drive the market growth. For instance, in July 2021, according to the report published by National Library of Medicine, the prevelance of idiopathic pulmonary fibrosis was 13 to 20 per 100,000 people worldwide in 2020. About 100,000 people were affected in the U.S., in 2020, whereas 30,000 to 40,000 new cases are diagnosed every year.

According to the report published by National Center for Biotechnology Information, the prevalence of Idiopathic pulmonary fibrosis in India was found to be approximately 13.7% in 2021.

Furthermore, due to increasing prevalence of Idiopathic pulmonary fibrosis, the key market players are focusing on new product launches, and this is expected to drive the market growth over the forecast period. For instance, in May 2022, Sandoz, a global leader in generic and biosimilar medicines, announced the launch of its generic Pirfenidone in the U.S., the first AB-rated (Antibody)(fully substitutable) equivalent to Genentech’s, a biotechnology company, Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF). This oral medicine is prescribed to patients via specialty pharmacies

Key features of the study:

This report provides in-depth analysis of the global Idiopathic pulmonary fibrosis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Idiopathic pulmonary fibrosis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global Idiopathic pulmonary fibrosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Idiopathic pulmonary fibrosis market

Detailed Segmentation:

Global Idiopathic pulmonary fibrosis market, By Drug:

Pirfenidone

Nintedanib

Others (Interferon gamma-1b and Others)

Global Idiopathic pulmonary fibrosis market, By Route of Administration:

Oral

Parenteral

Global Idiopathic pulmonary fibrosis market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Idiopathic pulmonary fibrosis market, By Region:

North America

By Country:

U.S.

Canada

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

By Country

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

By Country:

GCC

Israel

Rest of Middle East

Africa

By Country/Region:

South Africa

Central Africa

North Africa

Company Profiles

Genentech, Inc.*

Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies

Boehringer Ingelheim International GmbH

Avalyn Pharma, Inc.

AstraZeneca

Blade Therapeutics

Bristol-Myers Squibb Company

Cipla Inc.

Hoffmann-La Roche

FibroGen, Inc.

Galapagos NV

MediciNova, Inc.

Merck & Co., Inc.

Promedior, Inc.

Prometic Life Sciences Inc.

Daewoong Pharmaceutical (India) Pvt Ltd

Sandoz International GmbH (Novartis)

Algernon Pharmaceuticals Inc.

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Drug; Market Snapshot, By Route of Administration; Market Snapshot, By Distribution Channel; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Attractiveness Analysis; Market Opportunities; Product Launches; Merger, Acquisition, Collaboration; Regulatory Guideline and Compliances; Key Developments; Market Trends; PEST Analysis; Epidemiology; PORTER’s Analysis; Regulatory Scenario; Brand Analysis; Pricing Analysis; Pipeline Analysis
4. Global Idiopathic Pulmonary Fibrosis Market- Impact of Coronavirus (Covid-19) Pandemic: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Idiopathic Pulmonary Fibrosis Market, By Drug, 2017 – 2030, (US$ Million): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Pirfenidone; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Nintedanib; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Others (Interferon gamma-1b and Others); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
6. Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration, 2017 – 2030, (US$ Million): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Oral; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Parenteral; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
7. Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, 2017 – 2030, (US$ Million): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segments Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
8. Global Idiopathic Pulmonary Fibrosis Market, By Region, 2017 – 2030, (US$ Million): Introduction; Market Share Analysis, By Region, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Region, 2017–2030; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-Region, 2017 – 2030, (US$ Million); North Africa; Central Africa; South Africa
9. Competitive Landscape: Genentech, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Boehringer Ingelheim International GmbH.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Avalyn Pharma, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; AstraZeneca; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Blade Therapeutics; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Bristol-Myers Squibb Company; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Cipla Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; F. Hoffmann-La Roche; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; FibroGen, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Galapagos NV; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; MediciNova, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Merck & Co., Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Promedior, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Prometic Life Sciences Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Daewoong Pharmaceutical (India) Pvt Ltd; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Sandoz International GmbH (Novartis); Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Algernon Pharmaceuticals Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; 10. Section; Research Methodology; About Us; *Browse 58 market data tables and 53 figures on “Global Idiopathic Pulmonary Fibrosis Market”- Global forecast to 2030